Know Cancer

or
forgot password

Hypercoagulability and Thromboembolic Risk in Patients With Malignant Disease, Evaluated by Thrombelastograph (TEG®)


N/A
18 Years
N/A
Open (Enrolling)
Both
Cancer

Thank you

Trial Information

Hypercoagulability and Thromboembolic Risk in Patients With Malignant Disease, Evaluated by Thrombelastograph (TEG®)


Inclusion Criteria:



- Clinical diagnosis of cancer

Exclusion Criteria:

- Mamma cancer

Type of Study:

Observational

Study Design:

Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal, Time Perspective: Prospective

Principal Investigator

Pär I Johansson, MD

Investigator Role:

Study Chair

Investigator Affiliation:

Rigshospitalet, Denmark

Authority:

Denmark: Ethics Committee

Study ID:

TEG-Onkologi

NCT ID:

NCT00400504

Start Date:

November 2006

Completion Date:

Related Keywords:

  • Cancer
  • Thrombelastograph
  • Cancer
  • Thromboembolism
  • Hypercoagulable
  • Thrombophilia

Name

Location